Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 12/20 | 0.51 |
| ▸ | PPARG | P37231 | 12/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | VDR | P11473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034601 | 0.88 | FFAR1 (0.52) | FFAR1PPARAPPARGPPARDMAPT | |
| SCHEMBL4034983 | 0.86 | KDR (0.53) | FFAR1PPARAPPARGKDM4EMAPT | |
| SCHEMBL4042286 | 0.86 | FFAR1 (0.48) | FFAR1PPARAPPARGMAPT | |
| SCHEMBL5402187 | 0.84 | POLB (0.53) | FFAR1PPARAPPARGKDM4EMAPT | |
| SCHEMBL4033057 | 0.84 | FFAR1 (0.48) | FFAR1PPARAPPARGKDM4EMAPT | |
| SCHEMBL5403576 | 0.84 | FFAR1 (0.79) | FFAR1PPARAPPARGPPARDVDR | |
| SCHEMBL4850543 | 0.84 | PPARG (0.61) | FFAR1PPARAPPARGPPARDKDM4E | |
| SCHEMBL4026930 | 0.82 | PPARA (0.70) | FFAR1PPARAPPARGPPARD | |
| SCHEMBL4032164 | 0.82 | FFAR1 (0.76) | FFAR1PPARAPPARGPPARDVDR | |
| SCHEMBL4032981 | 0.81 | PPARA (0.53) | FFAR1PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241785-B2 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | FFAR1 14/4885PPARA 301/4885PPARG 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.